Objective
to examine whether a high-dose infusion of bivalirudin after PCI in patients undergoing primary PCI for STEMI is superior to heparin monotherapy
Study
investigator, open-label, multicentre, randomised study
Population
patients with STEMI undergoing primary PCI with radial artery access within 48-hours of symptom onset
Endpoints
composite of all-cause mortality or BARC bleeding 3-5 types at 30 days
Conclusion
bivalirudin with high dose infusion (2-4h after PCI) resulted in a significant reduction of all-cause death and BARC-bleeding (types 3-5) as compared to heparin in patients with STEMI treated with primary PCI
Li et al. Lancet 2022;400:1847-57
